Potential roles of FGF5 as a candidate therapeutic target in prostate cancer

• Published in: American journal of clinical and experimental urology Vol. 11; no. 6; pp. 452 - 466
• Main Authors: Stangis, Mary M, Colah, Avan N, McLean, Dalton T, Halberg, Richard B, Collier, Lara S, Ricke, William A
• Format: Journal Article
• Language: English
• Published: United States e-Century Publishing Corporation 01.01.2023
• Subjects: Review; stromal-epithelial crosstalk; FGF5 inhibitors; prostate cancer; Fibroblast growth factor 5
• ISSN: 2330-1910; 2330-1910

Fibroblast growth factor (FGF) is a secreted ligand that is widely expressed in embryonic tissues but its expression decreases with age. In the developing prostate, FGF5 has been proposed to interact with the Hedgehog (Hh) signaling pathway to guide mitogenic processes. In the adult prostate, the FGF/FGFR signaling axis has been implicated in prostate carcinogenesis, but focused studies on FGF5 functions in the prostate are limited. Functional studies completed in other cancer models point towards FGF5 overexpression as an oncogenic driver associated with stemness, metastatic potential, proliferative capacity, and increased tumor grade. In this review, we explore the significance of FGF5 as a therapeutic target in prostate cancer (PCa) and other malignancies; and we introduce a potential route of investigation to link FGF5 to benign prostatic hyperplasia (BPH). PCa and BPH are two primary contributors to the disease burden of the aging male population and have severe implications on quality of life, psychological wellbeing, and survival. The development of new FGF5 inhibitors could potentially alleviate the health burden of PCa and BPH in the aging male population.